VR Adviser’s Akoya BioSciences AKYA Stock Holding History

VR Adviser’s Portfolio AKYA Stock Details AKYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-400,000	Closed	-$6.12M	–	28
2021 Q4	$6.12M	Hold	400,000	–	–	0.84%	24
2021 Q3	$5.58M	Hold	400,000	–	–	0.72%	23
2021 Q2	$7.74M	Buy	+400,000	New	+$8.26M	0.94%	25

Other funds holding AKYA

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

VR Adviser's AKYA Position: Q1 2022 in Review

VR Adviser sold out of Akoya BioSciences (AKYA) in Q1 2022, closing a stake of 400,000 shares — an estimated $6.12M sold.

VR Adviser first reported a position in AKYA in Q2 2021 and held it in 3 quarters. The position peaked at $7.74M in Q2 2021. 46 funds tracked by Wall St. Rank hold AKYA as of Q1 2022.

VR Adviser reported no remaining Akoya BioSciences position as of Q1 2022 after selling out during the quarter.
VR Adviser sold 400,000 Akoya BioSciences shares in Q1 2022, an estimated $6.12M.
VR Adviser first reported a position in Akoya BioSciences in Q2 2021 and held it in 3 quarters.
VR Adviser's Akoya BioSciences position peaked at $7.74M in Q2 2021.
46 funds tracked by Wall St. Rank held Akoya BioSciences as of Q1 2022.

Based on VR Adviser's 13F filing for Q1 2022, filed 16 May 2022.